Table 1.

SGLT2-I, GLP1-RA, And GIP/GLP-1 RA Use in Practice for Patients with Type 2 Diabetes

Therapy and dose rangeeGFR Cut-off for initiation for glycemic benefitAdditional indications for adults with type 2 diabetesMedian average wholesale price
SGLT2-Inhibitors
 Bexagliflozin (Brenzavvy), 20 mg  PO once daily30 mL/minn/a
 Canagliflozin (Invokana), 100 to  300 mg PO once daily30 mL/min

  • Established CVD: risk reduction of MACE

  • Diabetic nephropathy with albuminuria >300 mg/d: risk reduction of ESKD, serum creatinine doubling, CV death, and HHF

$684
 Dapagliflozin (Farxiga), 5 to 10 mg  PO once daily45 mL/min

  • Established CVD or multiple CV risk factors: risk reduction of HHF

  • HFrEF: risk reduction of CV death and HHF

$659
 Empagliflozin (Jardiance), 10 to  25 mg PO once daily30 mL/min

  • Established CVD: risk reduction CV death

  • HFrEF and HFpEF: risk reduction CV death and HHF

$685
 Ertugliflozin (Steglatro), 5 to  15 mg PO once daily45 mL/min$390
GLP-1 receptor agonists and GIP/GLP-1 receptor agonists
 Dulaglutide (Trulicity), 0.75- 4.5 mg weekly injectionn/a

  • Established CVD or multiple CV risk factors: risk reduction MACE

$1,064
 Exenatide (Byetta), 5 to 10 mcg  twice daily injection30 mL/min$961
 Exenatide XR (Bydureon  BCise),2 mg weekly injection30 mL/min$936
 Liraglutide (Victoza), 0.6-1.8 mg  weekly injectionn/a

  • Established CVD: risk reduction MACE

$1,278
 Semaglutide (Ozempic), 0.25-2 mg  weekly injectionn/a

  • Established CVD: risk reduction MACE

$1,070
 Semaglutide (Rybelsus), 7 to 14 mg  PO once dailyn/a$1,070
GIP/GLP-1 receptor agonists
 Tirzepatiden/a$1,169

  • Abbreviations: eGFR, estimated glomerular filtration rate (mL/min/1.73 m2); MACE, major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke); ESKD, end-stage kidney disease; HHF, hospitalization for heart failure; HFrEF, heart failure with reduced ejection fraction; CKD, chronic kidney disease; HFpEF, Heart failure with preserved ejection fraction.